series-a
Stage
1
Investors
About
Syntis Bio develops oral therapies targeting the small intestine to treat metabolic health conditions such as obesity, diabetes, and rare diseases.
Explore Syntis Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.